Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FLIGHT Protocol: An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the Anti-PD1 Therapy

Next Previous
Trial Profile

FLIGHT Protocol: An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the Anti-PD1 Therapy

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs FLT-3 ligand (Primary) ; Glembatumumab vedotin; Nivolumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms FLIGHT

    • Most Recent Events

    • 14 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top